Drug Profile


Alternative Names: Cytolex; Locilex; MSI-78; Pexiganan acetate

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genaera Corporation
  • Developer Genaera Corporation; PLx Pharma; RRD International
  • Class Antibacterials; Antimicrobial cationic peptides; Peptide antibiotics
  • Mechanism of Action Cell membrane permeability enhancers; Defensin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Diabetic foot ulcer
  • Preclinical Skin and soft tissue infections
  • Discontinued Impetigo

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Skin-and-soft-tissue-infections in USA (Topical, Cream)
  • 19 Apr 2017 Dipexium Pharmaceuticals has been acquired and merged into PLx Pharma
  • 28 Feb 2017 Dipexium Pharmaceuticals has patents pending for Pexiganan (Locilex®) in Brazil, Canada, China, Eurasia, Indonesia, Mexico, Singapore and South Africa (Dipexium Annual report 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top